Business Context and Reporting Period
This Form 6-K filing is submitted by Midatech Pharma PLC (not Biodexa Pharmaceuticals Plc as indicated in the request metadata) for the month of December 2019, specifically dated December 16, 2019. The registrant is a foreign private issuer headquartered in Cardiff, United Kingdom, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely as a vehicle to incorporate a press release by reference and contains no financial statements or quantitative performance data.
Material Changes
The material event disclosed in this filing is the receipt of a notice from NASDAQ, as detailed in the attached press release (Exhibit 99.1). No financial changes versus prior periods are reported in this text.
Guidance, Outlook, and Risks
The filing references a press release titled "Receipt of NASDAQ Notice." While the specific content of the notice is not detailed in the Form 6-K text itself, the receipt of such a notice typically indicates a potential risk regarding the company's continued listing status or compliance with exchange requirements. No specific guidance or management commentary on future operations is included in this filing text.
Investor Verification Checklist
- Verify the full text of the "Receipt of NASDAQ Notice" press release (Exhibit 99.1) to understand the specific compliance or listing issues raised.
- Confirm the company's current stock ticker and listing status on NASDAQ following this notice.
- Review subsequent filings for any updates on the resolution of the NASDAQ notice.
- Note the discrepancy between the request metadata (Biodexa) and the actual registrant (Midatech Pharma PLC).